OncoMatch/Clinical Trials/NCT05185505
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Is NCT05185505 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Atezolizumab and Bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab · Bevacizumab — Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Previous systemic therapy for HCC prior to study enrollment
Cannot have received: immune checkpoint blockade therapy
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Lymphocyte count ≥ 0.5 x 10^9/L; Platelet count > 75 x 10^9/L; Hemoglobin > 9 g/dL
Kidney function
Serum creatinine < 1.5x ULN or calculated creatinine clearance < 50 ml/min
Liver function
Total bilirubin < 1.5 x ULN; AST, ALT, ALP < 2.5 x ULN; Serum albumin > 2.7 g/dL; Child-Pugh score ≤A6
Adequate hematological and end-organ function, defined by the following laboratory test results obtained within 14 days prior to study initiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist Research Institute · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify